Peter De Boer
5PUBLICATIONS
5CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Apr 07, 2020
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial.Kasper Recourt, Jasper van der Aart, Gabriel Jacobs
|Jan 16, 2019
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia.Sander Brooks, Gabriël E Jacobs, Peter de Boer
|Sep 28, 2018
Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.Maarten Timmers, Paulien Ravenstijn, Liwen Xi
|Sep 06, 2018
Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects.Peter D van der Ark, Georg Golor, Luc van Nueten
|Jun 01, 2018
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.Peter De Boer, Wayne C Drevets, Hany Rofael
Pageof 1
